Pentwater Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Pentwater Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-295,690	Closed	-$6.22M	–	150
2015 Q2	$6.22M	Buy	295,690 +95,690	+48%	+$2.37M	0.03%	115
2015 Q1	$8.4M	Sell	200,000 -200,000	-50%	-$6.58M	0.06%	100
2014 Q4	$9.41M	Sell	400,000 -90,000	-18%	-$1.51M	0.07%	90
2014 Q3	$7.33M	Buy	+490,000	New	+$7.25M	0.07%	112

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

LCP

Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pentwater Capital Management's OCUL Position: Q3 2015 in Review

Pentwater Capital Management sold out of Ocular Therapeutix (OCUL) in Q3 2015, closing a stake of 295,690 shares — an estimated $6.22M sold.

Pentwater Capital Management first reported a position in OCUL in Q3 2014 and held it in 4 quarters. The position peaked at $9.41M in Q4 2014. 70 funds tracked by Wall St. Rank hold OCUL as of Q3 2015.

Pentwater Capital Management reported no remaining Ocular Therapeutix position as of Q3 2015 after selling out during the quarter.
Pentwater Capital Management sold 295,690 Ocular Therapeutix shares in Q3 2015, an estimated $6.22M.
Pentwater Capital Management first reported a position in Ocular Therapeutix in Q3 2014 and held it in 4 quarters.
Pentwater Capital Management's Ocular Therapeutix position peaked at $9.41M in Q4 2014.
70 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2015.

Based on Pentwater Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.